Raymond James Trust N.A. Has $451,000 Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Raymond James Trust N.A. lowered its stake in Illumina, Inc. (NASDAQ:ILMN) by 5.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,460 shares of the life sciences company’s stock after selling 213 shares during the period. Raymond James Trust N.A.’s holdings in Illumina were worth $451,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Versant Capital Management Inc increased its stake in shares of Illumina by 292.9% in the second quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock valued at $34,000 after buying an additional 246 shares during the period. Industrial Alliance Investment Management Inc. acquired a new position in Illumina in the 2nd quarter valued at approximately $34,000. Massmutual Trust Co. FSB ADV raised its stake in shares of Illumina by 65.1% during the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after acquiring an additional 168 shares during the last quarter. Itau Unibanco Holding S.A. acquired a new position in shares of Illumina during the second quarter worth $61,000. Finally, Mizuho Securities Co. Ltd. bought a new stake in shares of Illumina in the second quarter worth $63,000. Institutional investors own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on ILMN. Scotiabank cut their target price on Illumina from $176.00 to $164.00 and set a “sector outperform” rating on the stock in a report on Thursday, August 15th. TD Cowen boosted their price target on shares of Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. UBS Group increased their price objective on shares of Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Royal Bank of Canada boosted their target price on shares of Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. Finally, StockNews.com began coverage on Illumina in a research report on Thursday, August 29th. They issued a “buy” rating for the company. One analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Illumina presently has a consensus rating of “Moderate Buy” and a consensus target price of $164.00.

Illumina Stock Down 0.6 %

Shares of NASDAQ ILMN opened at $142.95 on Wednesday. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. Illumina, Inc. has a 1 year low of $93.51 and a 1 year high of $156.66. The stock has a market capitalization of $22.67 billion, a P/E ratio of -14.35 and a beta of 1.13. The company has a 50-day moving average price of $141.15 and a 200-day moving average price of $125.40.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The firm had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. During the same period in the previous year, the company posted $0.33 EPS. The company’s revenue for the quarter was down 3.5% on a year-over-year basis. On average, equities research analysts forecast that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.